These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37211960)

  • 1. Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis.
    Del Carpio LP; Algarra MA; Sabaté-Llobera A; Rodriguez-Vida A; Rossi-Seoane S; Ruiz S; Leiva D; Ramos E; Lladò L; Lorenzo D; Gutierrez C; Cortes-Romera M; Caminal JM; Piulats JM
    Cancer Med; 2023 Jul; 12(13):14062-14071. PubMed ID: 37211960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.
    Strobel K; Bode B; Dummer R; Veit-Haibach P; Fischer DR; Imhof L; Goldinger S; Steinert HC; von Schulthess GK
    Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1774-82. PubMed ID: 19495748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
    Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
    Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic activity of primary uveal melanoma on PET/CT scan and its relationship with monosomy 3 and other prognostic factors.
    Papastefanou VP; Islam S; Szyszko T; Grantham M; Sagoo MS; Cohen VM
    Br J Ophthalmol; 2014 Dec; 98(12):1659-65. PubMed ID: 25084771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staging Uveal Melanoma with Whole-Body Positron-Emission Tomography/Computed Tomography and Abdominal Ultrasound: Low Incidence of Metastatic Disease, High Incidence of Second Primary Cancers.
    Cohen VML; Pavlidou E; DaCosta J; Arora AK; Szyszko T; Sagoo MS; Szlosarek P
    Middle East Afr J Ophthalmol; 2018; 25(2):91-95. PubMed ID: 30122854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma.
    Klingenstein A; Haug AR; Nentwich MM; Tiling R; Schaller UC
    Melanoma Res; 2010 Dec; 20(6):511-6. PubMed ID: 20890225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lactate Dehydrogenase Prior to Transarterial Hepatic Chemoperfusion Predicts Survival and Time to Progression in Patients with Uveal Melanoma Liver Metastases.
    Ludwig J; Haubold J; Heusner TA; Bauer S; Siveke JT; Richly H; Wetter A; Umutlu L; Theysohn JM
    Rofo; 2021 Jun; 193(6):683-691. PubMed ID: 33348383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET).
    Servois V; Mariani P; Malhaire C; Petras S; Piperno-Neumann S; Plancher C; Levy-Gabriel C; Lumbroso-le Rouic L; Desjardins L; Salmon RJ
    Eur J Surg Oncol; 2010 Feb; 36(2):189-94. PubMed ID: 19775851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between survival and maximum standardized uptake value of liver metastases detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography in patients with adenocarcinoma of unknown primary origin.
    Algin E; Ozet A; Gumusay O; Cetin B; Akdemir UO; Benekli M; Coskun U; Uner A; Kapucu O; Buyukberber S
    Ann Nucl Med; 2014 Nov; 28(9):891-6. PubMed ID: 25270711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.
    Khoja L; Atenafu EG; Suciu S; Leyvraz S; Sato T; Marshall E; Keilholz U; Zimmer L; Patel SP; Piperno-Neumann S; Piulats J; Kivelä TT; Pfoehler C; Bhatia S; Huppert P; Van Iersel LBJ; De Vries IJM; Penel N; Vogl T; Cheng T; Fiorentini G; Mouriaux F; Tarhini A; Patel PM; Carvajal R; Joshua AM
    Ann Oncol; 2019 Aug; 30(8):1370-1380. PubMed ID: 31150059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography.
    Eldredge-Hindy H; Ohri N; Anne PR; Eschelman D; Gonsalves C; Intenzo C; Bar-Ad V; Dicker A; Doyle L; Li J; Sato T
    Am J Clin Oncol; 2016 Apr; 39(2):189-95. PubMed ID: 24441583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
    Ding CY; Guo Z; Li YY; Li TR
    Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):828-834. PubMed ID: 29151289
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors.
    Bedikian AY; Legha SS; Mavligit G; Carrasco CH; Khorana S; Plager C; Papadopoulos N; Benjamin RS
    Cancer; 1995 Nov; 76(9):1665-70. PubMed ID: 8635073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience.
    Nicholas MN; Khoja L; Atenafu EG; Hogg D; Quirt I; Butler M; Joshua AM
    Melanoma Res; 2018 Dec; 28(6):571-577. PubMed ID: 30067547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer.
    Ulaner GA; Eaton A; Morris PG; Lilienstein J; Jhaveri K; Patil S; Fazio M; Larson S; Hudis CA; Jochelson MS
    Cancer Med; 2013 Oct; 2(5):725-33. PubMed ID: 24403238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic uveal melanoma: is there a role for conventional chemotherapy? - A single center study based on 58 patients.
    Pons F; Plana M; Caminal JM; Pera J; Fernandes I; Perez J; Garcia-Del-Muro X; Marcoval J; Penin R; Fabra A; Piulats JM
    Melanoma Res; 2011 Jun; 21(3):217-22. PubMed ID: 21467954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of metastatic disease in patients with uveal melanoma using positron emission tomography.
    Francken AB; Fulham MJ; Millward MJ; Thompson JF
    Eur J Surg Oncol; 2006 Sep; 32(7):780-4. PubMed ID: 16765562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors of liver metastases from uveal melanoma.
    Kodjikian L; Grange JD; Baldo S; Baillif S; Garweg JG; Rivoire M
    Graefes Arch Clin Exp Ophthalmol; 2005 Oct; 243(10):985-93. PubMed ID: 15891893
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of baseline metabolic tumor volume measured on
    Ito K; Schöder H; Teng R; Humm JL; Ni A; Wolchok JD; Weber WA
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):930-939. PubMed ID: 30488098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.